Tearsheet

Aditxt (ADTX)

Market Price (12/4/2025): $2.75 | Market Cap: $51,147
Sector: Health Care | Industry: Biotechnology

Aditxt (ADTX)

Market Price (12/4/2025): $2.75
Market Cap: $51,147
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -73%	Weak multi-year price returns 2Y Excs Rtn is -151%, 3Y Excs Rtn is -173%	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -22 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -183492%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more.		Debt is significant Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 36874%
2			Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -96%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -28%, Rev Chg QQuarterly Revenue Change % is -98%
3			Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -187615%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -187615%
4			Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -179661%
5			High stock price volatility Vol 12M is 10864%
6			Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 65%

0	Valuation becoming less expensive P/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -73%
1	Megatrend and thematic drivers Megatrends include Precision Medicine, and Biotechnology & Genomics. Themes include Personalized Diagnostics, Targeted Therapies, Show more.
2	Weak multi-year price returns 2Y Excs Rtn is -151%, 3Y Excs Rtn is -173%
3	Not profitable at operating income level Op Inc LTMOperating Income, Last Twelve Months is -22 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -183492%
4	Debt is significant Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is 36874%
5	Weak revenue growth Rev Chg LTMRevenue Change % Last Twelve Months (LTM) is -96%, Rev Chg 3Y AvgRevenue Change % averaged over trailing 3 years is -28%, Rev Chg QQuarterly Revenue Change % is -98%
6	Not cash flow generative CFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -187615%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -187615%
7	Yield minus risk free rate is negative ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -179661%
8	High stock price volatility Vol 12M is 10864%
9	Significant short interest Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 65%

Valuation, Metrics & Events

	12/4/25	2024	2023	2022	2021
Share Price CYE	$2.75	$5,361.85	$7,491,900.00	$52,187,920.00	$1,211,586,000.00
Market Cap CYE ($ Mil)	0.1	695.3	981.4	521.9	2,423.2
Total Debt ($ Mil)	5.5	6.9	18.2	3.4	4.7
Total Cash ($ Mil)	0.3	0.8	0.1	2.8	7.9
Enterprise Value ($ Mil)	5.2	702.2	999.6	525.3	2,427.9
Valuation Ratios
P/S TTM	1.2	45.9	13.5	5.0	204.2
P/EBIT TTM	0.0	-0.2	-0.3	-0.2	-0.5
P/E TTM	0.0	-0.2	-0.3	-0.2	-0.5
Sector Ratios
P/S TTM (Sector)	2.3	1.9	2.2	3.8	3.5
P/EBIT TTM (Sector)	299.4	16.8	17.3	15.6	14.6
P/E TTM (Sector)	-69.7	95.4	21.3	23.7	18.6

	12/4/25	2024	2023
Share Price CYE	$2.75	$5,361.85	$7,491,900.00
Market Cap CYE ($ Mil)	0.1	695.3	981.4
Total Debt ($ Mil)	5.5	6.9	18.2
Total Cash ($ Mil)	0.3	0.8	0.1
Enterprise Value ($ Mil)	5.2	702.2	999.6
Valuation Ratios
P/S TTM	1.2	45.9	13.5
P/EBIT TTM	0.0	-0.2	-0.3
P/E TTM	0.0	-0.2	-0.3
Sector Ratios
P/S TTM (Sector)	2.3	1.9	2.2
P/EBIT TTM (Sector)	299.4	16.8	17.3
P/E TTM (Sector)	-69.7	95.4	21.3

	ADTX	S&P 500
REVENUE GROWTH	VERY POOR
Rev LTM ($ Bil)	0.0
Rev Chg Q	-97.7%	7.1%
Rev Chg LTM	-96.3%	6.1%
Rev Chg 3Y Avg	-27.6%	5.5%
PROFITABILITY	VERY POOR
Op Inc LTM ($ Bil)	-0.0
CFO LTM ($ Bil)	-0.0
Net Inc LTM ($ Bil)	-0.0
Op Mgn LTM	-183,491.7%	18.8%
CFO/Rev LTM	-187,614.7%	20.5%
Net Inc Mgn	-208,565.7%	13.1%
VALUATION	LOW
P/S	1.2	3.2
P/CFO	-0.0	15.8
P/FCF	-0.0	20.5
P/E	-0.0	23.5
STABILITY	VERY POOR
Debt/Equity	391.88	0.20
Cash/Assets	0.01	0.07

AI Generated Analysis | Feedback

Metric	Value	Date	Source
Granted Patents	96	8252025	Link
Pending Patents	22	8252025	Link

Recent
11/17/2025	Earnings Release	Rev: $748 (A) vs. $null (E) EPS: -73.15 (A) vs. $null (E)

ADTX Stock

Return (1M):

null

Why The Stock Moved

Qualitative Assessment

AI Generated Analysis | Feedback

Here are the key points explaining the significant decline in Aditxt (ADTX) stock, particularly during the approximate period from August 31, 2025, to December 4, 2025:

1. Multiple Reverse Stock Splits Aditxt undertook multiple reverse stock splits, including a 1-for-250 reverse stock split on March 17, 2025, and a 1-for-113 reverse stock split effective November 3, 2025. These actions, often signaling financial distress and used to meet Nasdaq's minimum bid price requirement, typically lead to a decrease in liquidity and negative investor sentiment, contributing significantly to stock price erosion.

2. Persistent Nasdaq Delisting Risk The company has repeatedly faced notifications from Nasdaq regarding non-compliance with the minimum bid price requirement. While Aditxt may have temporarily regained compliance, the continuous need for reverse stock splits to maintain its listing highlights ongoing financial instability and poses a significant risk to investors, fostering uncertainty and selling pressure.

3. Severe Financial Challenges and Operational Underperformance Aditxt has exhibited significant financial weaknesses, including deeply negative gross profit margins (e.g., -916% as of May 30, 2025), minimal revenue, a high debt burden, and rapid cash burn. These fundamental operational challenges severely impact investor confidence and the company's valuation.

4. Uncertainty Surrounding Acquisitions and Financing Strategy Aditxt's planned acquisitions of companies like Appili Therapeutics and Evofem Biosciences have been contingent on securing sufficient capital and shareholder approval, creating uncertainty. Furthermore, the company temporarily halted equity financing activities to focus on debt financing for its acquisition strategy, which can signal financial strain and adds to investor apprehension.

5. Negative Investor Sentiment and Market Conditions Beyond specific corporate actions, the overall market conditions and negative investor sentiment towards the biotech sector, particularly for companies facing significant financial and operational hurdles, have contributed to the stock's decline. Reverse splits often signal distress or restructuring, causing investors to question company health and pull back.

Show less

Stock Movement Drivers

Fundamental Drivers

The -97.6% change in ADTX stock from 9/3/2025 to 12/3/2025 was primarily driven by a -97.6% change in the company's P/S Multiple.

	9032025	12032025	Change
Stock Price ($)	112.45	2.75	-97.55%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.01	0.01	0.00%
P/S Multiple	173.55	4.24	-97.55%
Shares Outstanding (Mil)	0.02	0.02	0.00%
Cumulative Contribution			-97.55%

LTM = Last Twelve Months as of date shown

Market Drivers

9/3/2025 to 12/3/2025

	Return	Correlation
ADTX	-97.6%
Market (SPY)	6.2%	1.7%
Sector (XLV)	13.3%	-0.7%

Fundamental Drivers

The -98.4% change in ADTX stock from 6/4/2025 to 12/3/2025 was primarily driven by a -198.7% change in the company's Shares Outstanding (Mil).

	6042025	12032025	Change
Stock Price ($)	176.28	2.75	-98.44%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.06	0.01	-78.22%
P/S Multiple	19.84	4.24	-78.61%
Shares Outstanding (Mil)	0.01	0.02	-198.68%
Cumulative Contribution			-104.60%

LTM = Last Twelve Months as of date shown

Market Drivers

6/4/2025 to 12/3/2025

	Return	Correlation
ADTX	-98.4%
Market (SPY)	15.1%	1.1%
Sector (XLV)	16.9%	0.2%

Fundamental Drivers

The -100.0% change in ADTX stock from 12/3/2024 to 12/3/2025 was primarily driven by a -775.2% change in the company's Shares Outstanding (Mil).

	12032024	12032025	Change
Stock Price ($)	10184.12	2.75	-99.97%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.21	0.01	-94.32%
P/S Multiple	102.03	4.24	-95.84%
Shares Outstanding (Mil)	0.00	0.02	-775.25%
Cumulative Contribution			-101.60%

LTM = Last Twelve Months as of date shown

Market Drivers

12/3/2024 to 12/3/2025

	Return	Correlation
ADTX	-100.0%
Market (SPY)	14.3%	0.7%
Sector (XLV)	7.0%	0.7%

Fundamental Drivers

The -100.0% change in ADTX stock from 12/4/2022 to 12/3/2025 was primarily driven by a -206555.6% change in the company's Shares Outstanding (Mil).

	12042022	12032025	Change
Stock Price ($)	80456000.00	2.75	-100.00%
Change Contribution By	LTM	LTM
Total Revenues ($ Mil)	0.85	0.01	-98.59%
P/S Multiple	848.74	4.24	-99.50%
Shares Outstanding (Mil)	0.00	0.02	-206555.56%
Cumulative Contribution			-114.58%

LTM = Last Twelve Months as of date shown

Market Drivers

12/4/2023 to 12/3/2025

	Return	Correlation
ADTX	-100.0%
Market (SPY)	53.2%	0.5%
Sector (XLV)	20.8%	0.6%

Return vs. Risk

Price Returns Compared

	2020	2021	2022	2023	2024	2025	Total [1]
Returns
ADTX Return	-	-74%	-96%	-86%	-100%	-100%	-100%
Peers Return	2%	-1%	6%	8%	-0%	2%	17%
S&P 500 Return	16%	27%	-19%	24%	23%	16%	112%
Monthly Win Rates [3]
ADTX Win Rate	33%	17%	17%	33%	0%	0%
Peers Win Rate	13%	8%	13%	12%	10%	90%
S&P 500 Win Rate	58%	75%	42%	67%	75%	70%
Max Drawdowns [4]
ADTX Max Drawdown	-	-74%	-96%	-93%	-100%	-100%
Peers Max Drawdown	-2%	-5%	0%	-0%	-1%	-2%
S&P 500 Max Drawdown	-31%	-1%	-25%	-1%	-2%	-15%

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, AIXC, ALPS, BBOT, EVMN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 12/3/2025 (YTD)

How Low Can It Go

Unique Key	Event	ADTX	S&P 500
2022 Inflation Shock	2022 Inflation Shock
2022 Inflation Shock% Loss	% Loss	-100.0%	-25.4%
2022 Inflation Shock% Gain to Breakeven	% Gain to Breakeven	310224.5%	34.1%
2022 Inflation ShockTime to Breakeven	Time to Breakeven	Not Fully Recovered days	464 days
2020 Covid Pandemic	2020 Covid Pandemic
2020 Covid Pandemic% Loss	% Loss	-77.6%	-33.9%
2020 Covid Pandemic% Gain to Breakeven	% Gain to Breakeven	345.7%	51.3%
2020 Covid PandemicTime to Breakeven	Time to Breakeven	Not Fully Recovered days	148 days

Compare to VRTX, AIXC, ALPS, BBOT, EVMN

In The Past

Aditxt's stock fell -100.0% during the 2022 Inflation Shock from a high on 2/11/2021. A -100.0% loss requires a 310224.5% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About Aditxt (ADTX)

Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.

AI Generated Analysis | Feedback

Here are 1-3 brief analogies for Aditxt (ADTX):

23andMe for your immune system. (It provides personalized insights into your immune health.)
CarFax for your immune system's health history. (It offers comprehensive reports and monitoring of your immune system's status over time.)
Google Analytics for your immune system's health. (It provides a detailed 'dashboard' and insights into your immune system's performance and trends.)

AI Generated Analysis | Feedback

AditxtScore™: A personalized immune health monitoring platform that provides a comprehensive profile of an individual's immune system.
AditxtExpress™: A network of clinical locations offering access to AditxtScore™ testing and other immune health services.

AI Generated Analysis | Feedback

Aditxt (ADTX) primarily sells its diagnostic testing services and collaborates on research and development with other companies. According to its latest available SEC filings (Form 10-K for the fiscal year ended December 31, 2023), no single customer accounted for 10% or more of its total revenue. Therefore, Aditxt does not have individually named "major customers" that constitute a significant portion of its sales. Instead, the company serves various categories of businesses:

Healthcare providers (e.g., hospitals, clinics, diagnostic laboratories)
Clinical research organizations (CROs)
Pharmaceutical companies
Research institutions (e.g., universities, government research labs)

AI Generated Analysis | Feedback

Thermo Fisher Scientific, Inc. (Symbol: TMO)
Agilent Technologies, Inc. (Symbol: A)

AI Generated Analysis | Feedback

Amro Albanna Co-founder, Chairman, and Chief Executive Officer Mr. Albanna co-founded Aditxt in 2017 and has served as CEO since January 2017. He is described as an innovation entrepreneur with 25 years of experience launching and growing companies around promising technologies. Prior to Aditxt, he founded eight startups across various industries, including healthtech, nanotechnology, enterprise software, research incubation, GPS & wireless, nano sensors, consumer health, and e-commerce. Mr. Albanna has a history of exiting ventures through mergers and acquisitions and taking companies public on exchanges like the American Stock Exchange, NASDAQ, OTC, and Frankfurt Stock Exchange. Thomas J. Farley, CPA Chief Financial Officer Mr. Farley serves as the Chief Financial Officer of Aditxt. His background includes serving as the Controller and Treasurer of Business Development Corporation of America ("BDCA"), a publicly listed business development company, from December 2015 to June 2020. Before that, from January 2011 to August 2015, he was the Senior Controller of Blackrock Capital Investment Corporation (NASDAQ: BKCC). Mr. Farley's experience also includes roles as a Senior Controller for PineBridge Investments Emerging Markets practice and an Accounting Manager for Bessemer Venture Partners. Shahrokh Shabahang, MS, PhD Co-founder, Chief Innovation Officer, Board Member Dr. Shabahang is a co-founder of Aditxt and serves as the Chief Innovation Officer and a Board Member. He brings over 20 years of experience in commercializing life science technologies. Corinne Pankovcin, CPA, MBA Chief Mergers & Acquisitions Officer Ms. Pankovcin is the Chief Mergers & Acquisitions Officer at Aditxt. She has a background that includes serving as Chief Financial Officer for several world-class organizations, including Business Development Corporation of America ("BDCA"), BlackRock Kelso Capital (NASDAQ BKCC), and AIG Capital Partners. In these roles, she was responsible for executing portfolio investments and managing significant M&A transactions. She also served as CFO of Aditxt since July 2020, effectively managing the company's growth as it became publicly traded on Nasdaq. Rowena Albanna Chief Operating Officer Ms. Albanna holds the position of Chief Operating Officer at Aditxt. She contributes over 20 years of leadership experience across the biotechnology, health innovation, and technology sectors.

AI Generated Analysis | Feedback

null

AI Generated Analysis | Feedback

Aditxt (ADTX) operates in several addressable markets with its main products and services:

AditxtScore™ for Immune Monitoring: The global immune response testing market was valued at USD 14 billion in 2024 and is anticipated to grow to USD 27.05 billion by 2033, with a CAGR of 7.6% from 2025 to 2033. The broader global immune monitoring solutions market is projected to grow at a CAGR of 12.9% from 2022 to 2027.
AditxtScore™ for COVID-19: The global COVID-19 diagnostics market was estimated at USD 48.64 billion for 2022.
Apoptotic DNA Immunotherapy (ADi™) / ADI-100 (for autoimmune diseases): The overall autoimmunity market is estimated at over USD 160 billion by 2030.
- Psoriasis Therapeutics (specific to ADI-100): The global psoriasis treatment market size was valued at USD 27.20 billion in 2024. It is projected to grow to USD 57.68 billion by 2032, exhibiting a CAGR of 10.2% during the forecast period. North America held a significant market share, valued at USD 20.32 billion in 2024. The U.S. psoriasis treatment market size is estimated at USD 10.10 billion in 2025 and is predicted to be worth around USD 20.53 billion by 2034.
- Type 1 Diabetes Therapeutics (specific to ADI-100): The global Type 1 Diabetes Treatment Market is projected to reach USD 14.3 billion by 2035, growing at a CAGR of 4.67% from 2025 to 2035. Another estimate places the global market at USD 16.97 billion in 2025, expected to reach USD 26.22 billion by 2032. The U.S. market accounted for 80.4% of global sales in 2023 (USD 2.2 billion) and is expected to reach USD 9.0 billion by 2033. North America held the largest revenue share in the global Type 1 diabetes market in 2024, accounting for 45.7%.
Apoptotic DNA Immunotherapy (ADi™) / ADI-100 (for transplanted organ rejection): The global organ and tissue transplantation and alternatives market is projected to reach USD 120.3 billion by 2024.
Pearsanta™ (Precision Diagnostics):
- Endometriosis Diagnostics: A global market of USD 1.45 billion.
- Prostate Cancer Diagnostics: The global prostate cancer diagnostics market size was estimated at USD 7,726.8 million in 2023 and is projected to reach USD 11,894.4 million by 2030, growing at a CAGR of 6.4% from 2024 to 2030. In 2024, North America dominated this market with a 46% share. The U.S. prostate cancer diagnostics market size was USD 3.15 billion in 2024 and is projected to be around USD 5.97 billion by 2034.
NeuroCap and NeuroEEG (EEG brain monitoring technologies): The global electroencephalography (EEG) devices market size was approximately USD 1.67 billion in 2024 and is predicted to grow to around USD 5.26 billion by 2034, with a CAGR of 11.1% from 2025 to 2034. The U.S. held a significant share of the North American market in 2023.
NeuroCap and NeuroEEG (Tele-neurology/Digital Health in Neurology): The global digital health in neurology market was estimated at USD 39.82 billion in 2024 and is predicted to surpass around USD 303.23 billion by 2034, expanding at a CAGR of 22.51% from 2025 to 2034. North America held the largest market share of 38% in 2024. The U.S. digital health in neurology market size was USD 13.32 billion in 2024 and is projected to be worth around USD 103.32 billion by 2034.

AI Generated Analysis | Feedback

Aditxt (ADTX) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily centered around its innovative biotechnology pipeline and strategic market initiatives:

Product Innovations in Immune System Health: Aditxt is focused on developing and commercializing technologies aimed at improving the health of the immune system. This includes the advancement of its proprietary AditxtScore platform and Adimune's therapeutic programs, which are undergoing preclinical studies for conditions such as psoriasis, diabetes, and Stiff Person Syndrome. These innovations aim to prevent immune system attacks, addressing the root causes of these conditions.
Expansion of Diagnostic Capabilities through Pearsanta: The company is expanding its diagnostic capabilities through its subsidiary, Pearsanta. A significant driver is the development of a blood-based diagnostic test for endometriosis, which has begun its first human study. Pearsanta is also preparing for a potential initial public offering (IPO), leveraging its focus on breakthroughs in cancer detection.
Strategic Collaborations, Licensing, Acquisitions, and Partnerships: Aditxt's revenue trajectory is expected to be influenced by strategic collaborations, licensing agreements, acquisitions, and partnerships. The company is actively pursuing these external growth strategies to broaden its market reach and enhance its product offerings.
Market Expansion: Aditxt is evaluating opportunities to expand its presence within existing markets and penetrate new geographical areas, aiming to broaden the reach of its technologies and services.

AI Generated Analysis | Feedback

Share Issuance

Aditxt completed its initial public offering in June 2020, pricing 1,226,668 units at $9.00 per unit, raising approximately $11.0 million. Each unit included one share of common stock and two types of warrants.
The company has implemented multiple reverse stock splits, including a 1-for-250 reverse split effective March 17, 2025, and a 1-for-113 reverse split effective November 3, 2025, primarily to maintain compliance with Nasdaq's minimum bid price requirement.
In July 2024, Aditxt secured $500,000 in cash proceeds from an accredited investor through the issuance of a senior note and a warrant to purchase up to 1,250,000 shares of common stock. Additionally, the company raised nearly a million dollars through senior notes and an additional $4.2 million in a private placement.

Inbound Investments

In July 2024, Aditxt received $500,000 in cash proceeds as part of a strategic financing agreement with an accredited investor, involving a senior note and warrants.
As part of its merger strategy with Evofem Biosciences, Aditxt made equity investments, including an adjusted third investment of $720,000 and a fourth of $2.28 million. Additionally, in April 2025, Aditxt invested $1.5 million in Evofem in exchange for a convertible note and a warrant.

Outbound Investments

Aditxt has pursued an M&A strategy, notably acquiring Appili Therapeutics in April 2024, although the arrangement agreement was later terminated in May 2025.
The company is in the process of merging with Evofem Biosciences, which was acquired in December 2023.
Aditxt completed the acquisition of Pearsanta in early 2024, and had also acquired AiPharma in December and October 2021.

Capital Expenditures

Aditxt's reported capital expenditures have been in the range of N/A, -$14 thousand, -$367 thousand, -$1,016 thousand, and -$171 thousand in various periods.

Better Bets than Aditxt (ADTX)

	ADTX	Better Performance than ADTX
Metric	Value	INDUSTRY: Biotechnology
Rev Chg LTM	-96.3%	AMGN (10.6%), VRTX (10.3%), ABBV (7.4%), REGN (2.9%), GILD (2.8%)
Rev Chg 3Y Avg	-27.6%	AMGN (11.2%), VRTX (10.5%), GILD (2.3%), REGN (1.4%), ABBV (1.2%)
Op Mgn LTM	-183491.7%	GILD (38.3%), REGN (26.7%), AMGN (24.1%), ABBV (24.1%), VRTX (-0.8%)
CFO/Rev LTM	-187614.7%	AMGN (36.5%), REGN (35.6%), ABBV (35.0%), GILD (33.2%), VRTX (31.7%)
FCF/Rev LTM	-187614.7%	ABBV (33.0%), AMGN (32.1%), GILD (31.5%), VRTX (28.5%), REGN (27.2%)
Total Yield	-179656.6%	GILD (8.8%), REGN (8.3%), AMGN (7.9%), VRTX (3.7%), ABBV (3.4%)
P/S	1.2	FTRE (0.3), ATRA (0.5), CHRS (0.7), SRPT (0.8), MYGN (0.8)
P/Op Inc	0.0

	ADTX	Better Performance than ADTX
Metric	Value	SECTOR: Health Care
Rev Chg LTM	-96.3%	LLY (36.8%), UNH (10.5%), ABBV (7.4%), JNJ (5.1%), MRK (1.7%)
Rev Chg 3Y Avg	-27.6%	LLY (23.4%), UNH (11.4%), JNJ (6.1%), MRK (2.9%), ABBV (1.2%)
Op Mgn LTM	-183491.7%	LLY (43.0%), MRK (34.9%), JNJ (26.2%), ABBV (24.1%), UNH (6.1%)
CFO/Rev LTM	-187614.7%	ABBV (35.0%), MRK (26.6%), JNJ (26.3%), LLY (20.5%), UNH (4.8%)
FCF/Rev LTM	-187614.7%	ABBV (33.0%), MRK (20.3%), JNJ (20.3%), UNH (4.0%), LLY (-0.1%)
Total Yield	-179656.6%	MRK (13.0%), JNJ (8.4%), UNH (8.1%), ABBV (3.4%), LLY (2.7%)
P/S	1.2	CVS (0.2), MCK (0.2), CI (0.3), ELV (0.4), UNH (0.7)
P/Op Inc	0.0

	ADTX	Better Performance than ADTX
Metric	Value	ALL OTHER SECTORS
Rev Chg LTM	-96.3%	NVDA (71.6%), MSFT (15.6%), GOOGL (13.4%), AMZN (10.9%), AAPL (6.0%)
Rev Chg 3Y Avg	-27.6%	NVDA (92.0%), MSFT (13.2%), AMZN (11.3%), GOOGL (11.0%), AAPL (1.8%)
Op Mgn LTM	-183491.7%	NVDA (58.1%), MSFT (46.3%), GOOGL (32.2%), AAPL (31.9%), AMZN (11.4%)
CFO/Rev LTM	-187614.7%	MSFT (50.0%), NVDA (46.6%), GOOGL (39.3%), AAPL (26.6%), AMZN (18.1%)
FCF/Rev LTM	-187614.7%	NVDA (43.6%), MSFT (26.6%), AAPL (23.5%), GOOGL (19.1%), AMZN (2.0%)
Total Yield	-179656.6%	GOOGL (4.6%), MSFT (3.4%), AMZN (3.0%), AAPL (3.0%), NVDA (2.3%)
P/S	1.2	GM (0.3), UPS (0.8), DELL (0.8), CMCSA (0.9), WMT (1.1)
P/Op Inc	0.0

		Best Bets In Health Care Sector
	ADTX
What You Pay
P/E	-0.0
P/EBIT	-0.0
What You Get
Rev Chg Q	-97.7%
Rev Chg LTM	-96.3%
Rev Chg 3Y Avg	-27.6%
FCF/Rev 3Y Avg	-65,352.2%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

	Title	Topic
0	DASHBOARDS
1	Aditxt Stock Plummets -55% With 7-Day Losing Streak	Notification
2	Day 7 of Loss Streak for Aditxt Stock with -80% Return (vs. -100% YTD) [10/31/2025]	Notification
3	Day 6 of Loss Streak for Aditxt Stock with -77% Return (vs. -100% YTD) [10/30/2025]	Notification
4	Day 5 of Loss Streak for Aditxt Stock with -62% Return (vs. -100% YTD) [10/29/2025]	Notification
5	Aditxt Stock Drop Looks Sharp, But How Deep Can It Go?	Return

	Title
0	ARTICLES

Trade Ideas

Select past ideas related to ADTX. For more, see Trefis Trade Ideas.

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	4.1%	4.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-9.8%	-9.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.0%	6.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.7%	9.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	6.2%	6.2%	-5.1%

Unique Key	Date	Ticker	Company	Category	Trade Strategy	6M Fwd Rtn	12M Fwd Rtn	12M Max DD
CRL_11142025_Dip_Buyer_FCFYield	11142025	CRL	Charles River Laboratories International	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	4.1%	4.1%	-3.7%
GDRX_11142025_Dip_Buyer_High_CFO_Margins_ExInd_DE	11142025	GDRX	GoodRx	Dip Buy	DB \| CFO/Rev \| Low D/EDip Buy with High Cash Flow Margins Buying dips for companies with significant cash flows from operations and reasonable debt / market cap	-9.8%	-9.8%	-11.8%
ASTH_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	ASTH	Astrana Health	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	6.0%	6.0%	-5.5%
SGRY_11142025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG	11142025	SGRY	Surgery Partners	Dip Buy	DB \| FCF Yield \| Low D/EDip Buy with High Free Cash Flow Yield Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap	9.7%	9.7%	-1.4%
TFX_11072025_Dip_Buyer_FCFYield	11072025	TFX	Teleflex	Dip Buy	DB \| FCFY OPMDip Buy with High FCF Yield and High Margin Buying dips for companies with high FCF yield and meaningfully high operating margin	6.2%	6.2%	-5.1%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

1 Month Top Gainers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
OLMA	Olema Pharmaceuticals	2.3	223.6%	367.4%
COGT	Cogent Biosciences	5.4	152.6%	402.1%
CDTX	Cidara Therapeutics	5.9	115.1%	722.1%
IRWD	Ironwood Pharmaceuticals	0.6	100.5%	-15.8%
TERN	Terns Pharmaceuticals	2.5	95.9%	396.2%
FRGE	Forge Global	0.6	90.3%	217.8%
SGML	Sigma Lithium	1.1	87.3%	-10.6%
INSP	Inspire Medical Systems	4.0	82.8%	-27.3%
NPCE	NeuroPace	0.6	77.2%	48.9%
ALMS	Alumis	0.6	71.9%	-0.3%

1 Month Top Losers

Ticker	Company	Mkt Cap (B)	1M Rtn	YTD Rtn
UP	Wheels Up Experience	0.4	-52.7%	-62.4%
CCOI	Cogent Communications	0.9	-51.9%	-72.9%
SMR	NuScale Power	3.0	-50.7%	12.3%
FRMI	Fermi	10.3	-47.5%
AMSC	American Superconductor	1.4	-47.2%	30.1%
TLRY	Tilray Brands	7.5	-46.1%	-46.9%
BTDR	Bitdeer Technologies	2.4	-44.8%	-41.8%
EXOD	Exodus Movement	0.4	-43.1%	-53.3%
STUB	Stubhub	3.5	-39.8%
METC	Ramaco Resources	1.0	-39.4%	66.9%

Recent Active Movers

1 Day Top Gainers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
MPLT	MapLight Therapeutics	0.7	31.3%
AEVA	Aeva Technologies	0.8	25.7%	188.2%
DC	Dakota Gold	0.6	19.7%	150.9%
SERV	Serve Robotics	0.7	18.2%	-12.6%
ACDC	ProFrac	0.7	17.6%	-45.0%
HY	Hyster Yale	0.6	15.6%	-29.9%
AEO	American Eagle Outfitters	4.1	15.1%	49.7%
BEAM	Beam Therapeutics	2.7	14.4%	7.8%
GOSS	Gossamer Bio	0.8	14.4%	278.1%
FTRE	Fortrea	1.3	14.4%	-21.8%

1 Day Top Losers

Ticker	Company	Mkt Cap (B)	1D Rtn	YTD Rtn
PSTG	Pure Storage	22.6	-27.3%	12.1%
GTLB	GitLab	6.3	-12.8%	-32.9%
CTEV	Claritev	0.7	-11.3%
FBYD	Falcons Beyond Global	0.7	-11.2%	131.2%
ACHC	Acadia Healthcare	1.3	-10.9%	-63.0%
ULS	UL Solutions	16.0	-10.7%	60.4%
HPK	HighPeak Energy	0.7	-10.6%	-59.8%
OS	OneStream	3.5	-10.4%	-35.0%
ARE	Alexandria Real Estate Equities	8.2	-10.1%	-47.9%
THO	Thor Industries	5.3	-9.5%	6.6%

1 Week Top Gainers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
HPP	Hudson Pacific Properties	6.3	641.5%	-34.3%
TLRY	Tilray Brands	7.5	618.1%	-46.9%
TMC	TMC The Metals	2.8	42.2%	589.3%
VERA	Vera Therapeutics	2.6	40.2%	-2.4%
ARWR	Arrowhead Pharmaceuticals	9.0	39.1%	246.1%
TE	T1 Energy	0.7	37.4%
MPLT	MapLight Therapeutics	0.7	32.1%
AEVA	Aeva Technologies	0.8	31.1%	188.2%
AMKR	Amkor Technology	10.9	30.2%	73.4%
DC	Dakota Gold	0.6	30.2%	150.9%

1 Week Top Losers

Ticker	Company	Mkt Cap (B)	1W Rtn	YTD Rtn
JANX	Janux Therapeutics	1.1	-50.7%	-68.0%
VTYX	Ventyx Biosciences	0.6	-25.0%	258.0%
CTEV	Claritev	0.7	-23.5%
AMBA	Ambarella	3.0	-22.9%	-3.6%
FULC	Fulcrum Therapeutics	0.6	-21.5%	92.8%
PD	PagerDuty	1.1	-20.5%	-33.9%
NTNX	Nutanix	12.7	-19.3%	-22.4%
CNK	Cinemark	2.6	-18.0%	-25.2%
PSTG	Pure Storage	22.6	-17.2%	12.1%
ZS	Zscaler	38.1	-15.9%	35.1%

Peer Comparisons for Aditxt

Peers to compare with:

Financials

	ADTX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Aditxt	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Mkt Price	2.75	463.13	2.54	1.07	11.07	21.22	6.91
Mkt Cap	0.0	118.4	-	-	-	-	59.2
Rev LTM	0	11,723	0	-	0	10	0
Op Inc LTM	-22	-92	-5	-	-93	-70	-70
FCF LTM	-23	3,337	-6	-	-60	-64	-23
FCF 3Y Avg	-22	2,064	-10	-	-	-	-10
CFO LTM	-23	3,718	-6	-	-60	-64	-23
CFO 3Y Avg	-22	2,419	-10	-	-	-	-10

Growth & Margins

	ADTX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Aditxt	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Rev Chg LTM	-96.3%	10.3%	-	-	-	-	-43.0%
Rev Chg 3Y Avg	-27.6%	10.5%	-	-	-	-	-8.6%
Rev Chg Q	-97.7%	11.0%	-	-	-	-	-43.4%
QoQ Delta Rev Chg LTM	-78.2%	2.7%	-	-	-	-	-37.8%
Op Mgn LTM	-183,491.7%	-0.8%	-	-	-	-700.7%	-700.7%
Op Mgn 3Y Avg	-65,367.1%	26.2%	-	-	-	-	-32,670.5%
QoQ Delta Op Mgn LTM	-143,840.6%	1.0%	-	-	-	-	-71,919.8%
CFO/Rev LTM	-187,614.7%	31.7%	-	-	-	-635.6%	-635.6%
CFO/Rev 3Y Avg	-65,347.8%	23.1%	-	-	-	-	-32,662.4%
FCF/Rev LTM	-187,614.7%	28.5%	-	-	-	-636.5%	-636.5%
FCF/Rev 3Y Avg	-65,352.2%	19.8%	-	-	-	-	-32,666.2%

Valuation

	ADTX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Aditxt	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
Mkt Cap	0.0	118.4	-	-	-	-	59.2
P/S	1.2	8.5	-	-	-	-	4.8
P/EBIT	-0.0	22.4	-	-	-	-	11.2
P/E	-0.0	27.2	-	-	-	-	13.6
P/CFO	-0.0	26.9	-	-	-	-	13.5
Total Yield	-179,656.6%	3.7%	-	-	-	-	-89,826.5%
Dividend Yield	0.0%	0.0%	-	-	-	-	0.0%
FCF Yield 3Y Avg	-57,395.7%	2.3%	-	-	-	-	-28,696.7%
D/E	391.9	0.0	-	-	-	-	195.9
Net D/E	368.7	-0.0	-	-	-	-	184.3

Returns

	ADTX	VRTX	AIXC	ALPS	BBOT	EVMN	Median
Name	Aditxt	Vertex P.	AIxCrypto	ALPS	BridgeBi.	Evommune
1M Rtn	-57.8%	8.7%	-	-	-9.9%	-	-9.9%
3M Rtn	-97.6%	16.8%	-	-	12.5%	-	12.5%
6M Rtn	-98.4%	3.9%	-	-	-	-	-47.3%
12M Rtn	-100.0%	1.3%	-	-	-	-	-49.3%
3Y Rtn	-100.0%	44.1%	-	-	-	-	-27.9%
1M Excs Rtn	-57.7%	8.7%	-	-	-9.9%	-	-9.9%
3M Excs Rtn	-102.8%	11.3%	-	-	4.5%	-	4.5%
6M Excs Rtn	-113.2%	-10.8%	-	-	-	-	-62.0%
12M Excs Rtn	-113.5%	-14.6%	-	-	-	-	-64.1%
3Y Excs Rtn	-172.8%	-25.9%	-	-	-	-	-99.4%

Financials

Annual
Quarterly

$ Mil \| FY: 12/31	LTM	2024	2023	2022	2021	2020	2019
Period End	6/30/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019
Filing Date	8/14/2025	3/31/2025	4/16/2024	4/17/2023	3/31/2022	3/25/2021	7/1/2020
Key Financials
Total Revenue	0	0	1	1	0	0	0
EBITDA	-21	-27	-25	-25	-44	-9	-6
Operating Income	-22	-28	-26	-25	-27	-9	-6
Net Income	-25	-34	-32	-28	-46	-9	-6
EPS	-7393.61	-311.18	-249623.74	-2768755.30	-23185682.00	-	-5827728.00
Growth Rates
Total Revenue Growth	-96.3%	-79.2%	-30.9%	789.0%	∞%	-	-
EBITDA Growth	36.0%	-6.2%	-2.5%	43.5%	-398.3%	-51.4%	-3.9%
Operating Income Growth	34.1%	-6.9%	-4.5%	9.1%	-209.2%	-51.1%	-4.7%
Net Income Growth	41.5%	-6.4%	-17.1%	40.4%	-406.8%	-57.0%	-2.4%
Margins
EBITDA Margin	-176043.4%	-20180.7%	-3945.9%	-2659.0%	-41849.8%	-	-
Operating Income Margin	-183491.7%	-20796.1%	-4039.6%	-2670.6%	-26120.0%	-	-
Net Income Margin	-208565.7%	-25709.2%	-5018.9%	-2961.3%	-44148.9%	-	-
Cash & Debt
Total Cash	0	1	0	3	8	11	0
Total Debt	5	7	18	3	5	2	0
Net Debt / (Cash)	5	6	18	1	-3	-9	0
Cash Flows
Net Cash from Operations	-23	-17	-19	-22	-22	-7	-0
Free Cash from Operations	-23	-17	-19	-23	-23	-7	-0
Returns to Shareholders
Dividends	0	-0	-0	-0	-0	-0	-0
Share Repurchases	7	3	0	0	-0	-0	-0

$ Mil \| FY: 12/31	2025Q2	2025Q1	2024Q4	2024Q3	2024Q2	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3
Period End	6/30/2025	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Filing Date	8/14/2025	5/15/2025	3/31/2025	11/18/2024	8/19/2024	5/20/2024	4/16/2024	11/14/2023	8/14/2023	5/15/2023	4/17/2023	11/14/2022
Key Financials Quarterly
Total Revenue	0	0	0	0	0	0	0	0	0	0	0	0
Ebitda	-6	-6	-5	-5	-6	-12	-8	-8	-4	-6	-8	-5
Operating Income	-6	-6	-6	-5	-6	-12	-8	-8	-4	-6	-8	-5
Net Income	-7	-6	-5	-7	-8	-15	-11	-10	-6	-6	-8	-8
EPS	-389.85	-917.56	-40.30	-6045.89	-37937.78	-88733.30	-84892.48	-275363.08	-355126.12	-498725.50	-822084.30	-839729.22
Key Financials TTM
Total Revenue TTM	0	0	0	0	0	1	1	1	1	1	1	1
Ebitda TTM	-21	-21	-27	-30	-33	-31	-25	-26	-23	-25	-25	-41
Operating Income TTM	-22	-22	-28	-30	-34	-32	-26	-26	-23	-25	-25	-27
Net Income TTM	-25	-25	-34	-40	-43	-41	-32	-30	-27	-28	-28	-44
Growth Rates Quarterly
Total Revenue Growth	-97.7%	-98.7%	-96.1%	-94.5%	-80.0%	-63.5%	-56.2%	-61.5%	2.9%	3.9%	76.7%	-
EBITDA Growth	-4.3%	52.4%	34.7%	42.8%	-42.0%	-105.8%	3.1%	-51.4%	27.3%	4.8%	66.5%	37.5%
Operating Income Growth	-3.0%	51.4%	28.9%	41.9%	-41.1%	-99.5%	-3.9%	-50.1%	26.6%	5.5%	19.4%	11.2%
Net Income Growth	3.9%	61.2%	52.3%	28.8%	-32.9%	-146.1%	-34.0%	-29.0%	2.9%	1.2%	66.0%	22.6%
Margins Quarterly
EBITDA Margin	-604400.2%	-542770.0%	-159680.0%	-66407.6%	-13139.3%	-14558.5%	-9552.5%	-6393.1%	-1854.2%	-2580.5%	-4317.9%	-1626.4%
Operating Income Margin	-612788.3%	-550895.4%	-177985.3%	-68588.2%	-13497.1%	-14477.5%	-9780.0%	-6502.9%	-1916.2%	-2647.2%	-4125.1%	-1668.8%
Net Income Margin	-722789.6%	-560934.1%	-164618.2%	-101262.2%	-17051.3%	-18486.1%	-13491.5%	-7828.9%	-2571.3%	-2740.1%	-4409.1%	-2338.9%
Cash & Debt
Total Cash	0	0	1	0	0	0	0	2	0	0	3	9
Total Debt	5	4	7	10	8	8	18	6	5	4	3	4
Net Debt / (Cash)	5	4	6	10	8	8	18	5	5	4	1	-6
Cash Flows Quarterly
FCF from Operations	-2	-12	-6	-2	-2	-6	-4	-8	-3	-4	-7	-8
Cash Flows TTM
FCF from Operations TTM	-23	-23	-17	-15	-20	-21	-19	-22	-22	-21	-22	-24
Returns to Shareholders Quarterly
Dividends	0	0	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	7	-0	-0	-0	-0	-0	-0	-0	-0	-0	-0
Return on Invested Capital (ROIC) Quarterly
ROIC	-12.4%	-11.6%	-12.4%	-10.6%	-14.6%	-28.8%	-19.7%	-27.7%	-15.7%	-22.1%	-30.4%	-23.0%
Return on Invested Capital (ROIC) TTM
ROIC TTM	-11.1%	-11.3%	-15.2%	-17.0%	-20.4%	-19.9%	-16.1%	-22.1%	-21.4%	-23.5%	-24.8%	-28.6%

Price Behavior

Price Behavior

Market Price	$2.75
Market Cap ($ Bil)	0.0
First Trading Date	06/30/2020
Distance from 52W High	-100.0%
	50 Days	200 Days
DMA Price	$32.50	$332.63
DMA Trend	down	down
Distance from DMA	-91.5%	-99.2%
	3M	1YR
Volatility	21,562.9%	10,907.9%
Downside Capture	1518.33	598.25
Upside Capture	-567.79	-272.97
Correlation (SPY)	2.1%	0.8%

ADTX Betas & Captures as of 11/30/2025

	1M	2M	3M	6M	1Y	3Y
Beta	127.32	45.77	31.18	14.37	3.99	1.94
Up Beta	-1509.73	-873.61	-672.59	-363.64	-43.13	-24.24
Down Beta	3.62	4.71	6.07	7.02	1.57	2.67
Up Capture	137009%	-456%	-328%	-147%	-55%	-6%
Bmk +ve Days	12	25	38	73	141	426
Stock +ve Days	8	14	19	44	84	267
Down Capture	793%	696%	606%	402%	170%	112%
Bmk -ve Days	7	16	24	52	107	323
Stock -ve Days	11	27	42	79	156	456

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

1Y 5Y 10Y

Based On 1-Year Data

		Comparison of ADTX With Other Asset Classes (Last 1Y)
	ADTX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-100.0%	6.9%	15.3%	58.9%	4.6%	-5.8%	-3.1%
Annualized Volatility	10,843.0%	17.2%	19.7%	19.4%	15.9%	17.8%	35.7%
Sharpe Ratio	0.93	0.23	0.60	2.26	0.09	-0.48	0.04
Correlation With Other Assets		0.7%	0.7%	0.3%	4.8%	-0.7%	-9.3%

ETFs used for asset classes: Sector ETF = XLV, Equity = SPY, Gold = GLD, Commodities = DBC, Real Estate = VNQ, and Bitcoin = BTCUSD
Smart multi-asset allocation framework can stack odds in your favor. Learn How

Based On 5-Year Data

		Comparison of ADTX With Other Asset Classes (Last 5Y)
	ADTX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-98.6%	9.0%	15.0%	17.9%	11.9%	4.9%	37.1%
Annualized Volatility	4,862.2%	14.4%	17.1%	15.5%	18.9%	19.0%	49.1%
Sharpe Ratio	0.39	0.44	0.71	0.93	0.52	0.17	0.64
Correlation With Other Assets		0.3%	0.5%	0.4%	1.8%	-0.4%	-3.1%

Based On 10-Year Data

		Comparison of ADTX With Other Asset Classes (Last 10Y)
	ADTX	Sector ETF	Equity	Gold	Commodities	Real Estate	Bitcoin
Annualized Return	-98.3%	9.9%	14.5%	14.2%	5.6%	5.4%	76.3%
Annualized Volatility	4,675.3%	16.7%	18.0%	14.8%	17.7%	20.9%	55.9%
Sharpe Ratio	0.38	0.49	0.69	0.79	0.25	0.23	0.95
Correlation With Other Assets		0.2%	0.5%	0.5%	1.8%	-0.4%	-3.0%

Short Interest

Short Interest: As Of Date	11142025
Short Interest: Shares Quantity	12,175
Short Interest: % Change Since 10312025	-99.0%
Average Daily Volume	79,054
Days-to-Cover Short Interest	1
Basic Shares Quantity	18,599
Short % of Basic Shares	65.5%

Returns Analyses

	Title
0	Aditxt Stock Drop Looks Sharp, But How Deep Can It Go?

SEC Filings

Expand for More

Report Date	Filing Date	Filing
6302025	8142025	10-Q 6/30/2025
3312025	5152025	10-Q 3/31/2025
12312024	3312025	10-K 12/31/2024
9302024	11182024	10-Q 9/30/2024
6302024	8192024	10-Q 6/30/2024
3312024	5202024	10-Q 3/31/2024
12312023	4162024	10-K 12/31/2023
9302023	11142023	10-Q 9/30/2023
6302023	8142023	10-Q 6/30/2023
3312023	5152023	10-Q 3/31/2023
12312022	4172023	10-K 12/31/2022
9302022	11142022	10-Q 9/30/2022
6302022	8152022	10-Q 6/30/2022
3312022	5162022	10-Q 3/31/2022
12312021	3312022	10-K 12/31/2021
9302021	11152021	10-Q 9/30/2021

Industry Resources

Health Care Resources

U.S. National Library of Medicine

Health Data Management

FDA Tracker

Biotechnology Resources

Fierce Biotech

Nature Biotechnology

Genetic Engineering & Biotechnology News

Biotechnology Innovation Organization

BioWorld

BioTechniques

HBS Biotechnology Publications

External Quote Links

0	Y Finance	Barrons
1	TradingView	Morningstar
2	SeekingAlpha	ValueLine
3	Motley Fool	Robinhood
4	CNBC	Etrade
5	MarketWatch	Unusual Whales
6	YCharts	Perplexity Finance
7	FinViz

Prefer one of these to Trefis? Tell us why.

Aditxt (ADTX)

Market Price (12/4/2025): $2.75 | Market Cap: $51,147Sector: Health Care | Industry: Biotechnology

Aditxt (ADTX)

Market Price (12/4/2025): $2.75Market Cap: $51,147Sector: Health CareIndustry: Biotechnology

Valuation, Metrics & Events

ADTX Stock

Why The Stock Moved

Qualitative Assessment

Stock Movement Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Fundamental Drivers

Market Drivers

Return vs. Risk

Price Returns Compared

How Low Can It Go

In The Past

Preserve Wealth

Asset Allocation

About Aditxt (ADTX)

Share Issuance

Inbound Investments

Outbound Investments

Capital Expenditures

Interactive Breakdown

Better Bets than Aditxt (ADTX)

Latest Trefis Analyses

Trade Ideas

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

1 Month Top Gainers

1 Month Top Losers

Recent Active Movers

1 Day Top Gainers

1 Day Top Losers

1 Week Top Gainers

1 Week Top Losers

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for Aditxt

Financials

Growth & Margins

Valuation

Returns

Comparison Analyses

FDIC Bank Data

Bank Capital

Bank Deposits

Bank Assets

Bank Loans

Financials

Segment Financials

Price Behavior

Based On 1-Year Data

Based On 5-Year Data

Based On 10-Year Data

Short Interest

Returns Analyses

Earnings Returns History

SEC Filings

Insider Activity

Industry Resources

External Quote Links

Market Price (12/4/2025): $2.75 | Market Cap: $51,147
Sector: Health Care | Industry: Biotechnology

Market Price (12/4/2025): $2.75
Market Cap: $51,147
Sector: Health Care
Industry: Biotechnology